For US Healthcare Professionals only.
VABOMERE® (meropenem and vaborbactam) is available for manual, automated, and semi-automated susceptibility testing.
The following susceptibility tests are approved for meropenem and vaborbactam:
Ordering Information
Ordering Information
For more information, contact your local bioMérieux representative or visit go.biomerieux.com/vitek. To place and track orders online, visit biomerieuxDIRECT.com or call 1-800-682-2666.
Ordering Information
Ordering Information
For more information, contact your local Beckman Coulter Microbiology representative, visit beckmancoulter.com or to order call (800) 526-3821.
Ordering Information
Ordering Information
For more information, contact your local BD Diagnostic Account Representative or visit
www.bd.com/en-us/offerings/capabilities/microbiology-solutions/identification-and-susceptibility-testing.
Ordering Information
Ordering Information
*Meropenem concentration 0.004-64 μg/mL-vaborbactam fixed concentration 8 μg/mL.
For more information, contact your local bioMérieux Inc. representative or call customer service at 800-682-2666 or visit www.biomerieux-usa.com/ETESTMEV.
To place an order, visit: www.biomerieuxDIRECT.com.
Ordering Information
Ordering Information
*Meropenem is a gradient in the MIC Strip: 0.016-256 μg/mL; vaborbactam is at fixed concentration along the strip.
For more information, contact liofilchem@liofilchem.net.
Ordering Information
Ordering Information
To order, visit hardydiagnostics.com or call 1-800-266-2222.
Ordering Information
Ordering Information
For more information, contact your local Thermo Fisher Scientific Microbiology representative at microbiology@thermofisher.com or visit thermofisher.com/AST.
For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Ordering and billingVABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.
Please see full Prescribing Information.